La presente informativa è resa, anche ai sensi dell’art. 13 del D. Lgs. 196/2003 “Codice in materia di protezione dei dati personali” (“Codice Privacy”) 
e degli artt. 13 e 14 del Regolamento (UE) 2016/679 (“GDPR”), a coloro che si collegano alla presente edizione online del giornale Tribuna Economica di proprietà di AFC Editore Soc. Coop. 

Leggi di più

The European Commission is referring Italy to the Court of Justice of the EU because its system of access to genetic resources from non-EU countries is considered to be dysfunctional. These dysfunctionalities damage the ability of companies established in Italy to tap

the benefits of such access for research, production and trade. Genetic resources are valuable genetic material of plant, animal, or microbial origin, such as medicinal plants, agricultural crops and animal breeds. The Access and Benefit-Sharing (ABS) requirements represent the guarantee that once a country facilitates access to its genetic resources and traditional knowledge (for example in relation to some active ingredient in a specific plant) it will have a share in the final product (new medicines etc.) developed on that basis.

Following a letter of formal notice sent by the Commission in January 2018 and a reasoned opinion in January 2019, Italy notified in July 2019 the designation of the national competent authorities. However, to date, Italy has not notified any legislation establishing the sanctions applicable for the violation of the rules.
The Commission has therefore decided to refer Italy to the Court of Justice of the EU.